“We are targeting a potential launch in late August for people with virally suppressed HIV, including those on complex regimens.”

In context

“ealized price due to channel mix. Looking at HIV treatment in more detail on slide nine, Biktarvy sales of $3.4 billion were up 7% year-over-year driven by higher demand and average realized price, partially offset by inventory drawdown. Sequentially, sales were down 15%, reflecting the first quarter seasonality that I just discussed. Biktarvy continues to lead as the regimen of choice for both naive and switch patients across major markets. In the U.S., Biktarvy's share was once again more than 52%, continuing its record of year-over-year gains in every quarter since launch. This market leadership is a testament to Biktarvy's differentiation and continued physician confidence. We also continue to innovate with bictegravir plus lenacapavir, or Biclen, our once-daily single-tablet regimen. We are targeting a potential launch in late August for people with virally suppressed HIV, including those on complex regimens. Building on our longstanding track record of delivering highly effective, differentiated therapies for people with HIV, we believe that Biclen is an exciting addition to our HIV treatment portfolio and has the potential to further expand Gilead Sciences, Inc.'s leadership in the switch market. Moving to slide 10, our U.S. HIV prevention, or PrEP, business grew 87% year-over-year, comprised of the market-leading branded daily oral Descovy and the first and only twice-yearly injectable Yes2Go. This performance was driven primarily by commercial execution and the strong product profiles of Descovy and Yes2Go. We believe we have the most compelling portfolio of PrEP products on the market and expect to retain and grow our leadership in the rapidly expanding PrEP market in both the near and lo”